CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022
CinCor Pharma, Inc. (NASDAQ: CINC) will report its fourth quarter and full year 2021 financial results before the U.S. markets open on March 22, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CinCor Pharma, Inc. (NASDAQ: CINC) will report its fourth quarter and full year 2021 financial results before the U.S. markets open on March 22, 2022. A conference call will occur at 8:30 AM Eastern Time to discuss the outcomes and business updates.
CinCor specializes in developing CIN-107, a selective oral inhibitor targeting aldosterone synthase for hypertension and other cardio-renal diseases. The live conference call can be accessed through the company’s website with a replay available for 30 days post-call.
Details
News Market Reaction – CINC
The recorded move for CINC in the trading session of this news was -0.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022. Following the announcement, the Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Tuesday, March 22, 2022 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 877-407-9039 |
| International: | 201-689-8470 |
| Conference ID: | 13727506 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1533175&tp_key=c99580e1e |
A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the CinCor Pharma, Inc. website or at the URL above. A replay will be available on the website approximately two hours following the live call for 30 days following the call. To access the live webcast, or the subsequent archived recording, please visit the Investors section of the CinCor website at www.CinCor.com.
About CinCor
CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO
Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.